Scarica l'app Stockscreener
372.18
3.18%
-12.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
Bio-Rad Laboratories, Inc. Class B (BIO.B) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Says - Yahoo Finance
Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 24 October - Investing.com UK
With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares. - Stock Titan
BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount? - Yahoo Finance
Form 4 BIO-RAD LABORATORIES: Sedat Evran (EVP, Global Supply Chain) For: 20 October By Investing.com - Investing.com South Africa
Sedat Evran Reports Vesting of 1,044 Bio-Rad RSUs with Tax Share Disposal on October 20, 2026 - Kalkine Media
Bio-Rad Laboratories, Inc. Class B (BIO.B) Earnings Dates, Call Summary & Reports - TipRanks
Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily
Quick ratio of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026 - Investing News Network
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates - Zacks Investment Research
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Bio-Rad Reports Second-Quarter 2026 Financial Results - Investing News Network
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Revenue Breakdown – HAN:BUWA - tradingview.com
Bio-Rad Laboratories Inc Stock Intrinsic Values | HAM:BUWA - gurufocus.com
Bio-Rad Laboratories Inc Stock Baskets - gurufocus.com
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
Weekly Recap: Bio-Rad growth and margin plan and digital PCR expansion - TradingView
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bio-Rad at bernstein healthcare forum: shift toward profitable growth By Investing.com - Investing.com UK
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - Zacks Investment Research
Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities - GlobeNewswire Inc.
Magnetic Bead Purification Kits Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
BIO-RAD LABORATORIES, INC. Executive Courtney C. Enloe Exercises 1,453 Stock Options at $0 (NYSE: BIO) - Kalkine Media
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Behavioral Patterns of BIO and Institutional Flows - Stock Traders Daily
4.22%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):